Dose reduction and discontinuation of alendronate in postmenopausal osteoporotic women who were receiving estrogen therapy.
D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004958:Estradiol / Q000627:therapeutic use; D004964:Estriol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D005269:Femur; D006207:Half-Life; D006801:Humans; D007044:Hysterectomy; D008159:Lumbar Vertebrae; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010919:Placebos
D004338:Drug Combinations; D010919:Placebos; C044003:estradiol, estriol drug combination; D004958:Estradiol; D004964:Estriol; D019386:Alendronate